Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced a collaboration and co-marketing
agreement with ImaBiotech for service offerings and product
development for Imaging Mass Cytometry™ (IMC™).
ImaBiotech is a contract research organization that offers
spatial multi-omics services to the pharmaceutical research
industry, specializing in precision medicine approaches to drug
efficacy and toxicity evaluations, from preclinical to clinical
stages. Through the acquisition of the Hyperion™ Imaging System,
the company will be offering Imaging Mass Cytometry as one if its
core technologies. ImaBiotech operates research facilities in
both the U.S. and Europe in the GLP (Good Laboratory Practice)
environment.
“We continuously evaluate technologies and develop robust and
effective protocols and applications to accelerate the development
of safe and effective therapies,” said Jonathan Stauber, PhD,
ImaBiotech CEO. “Our customers expressed a need for high-multiplex
imaging, and that compelled us to acquire a Hyperion Imaging System
to meet market needs. We are excited for the opportunity to
collaborate with Fluidigm in this regard, innovating applications
and products, including new panel development, to make Imaging Mass
Cytometry an even more powerful tool.”
ImaBiotech’s specialty services in high-parameter imaging are
utilized by more than 200 customers, most of which are
pharmaceutical companies.
“Partnering with a highly specialized imaging CRO that processes
hundreds of samples per week in a GLP environment is a great
opportunity for Fluidigm, and we are thrilled to partner with
ImaBiotech,” said Chris Linthwaite, Fluidigm President and CEO.
“This collaboration will showcase the unique capabilities of
Imaging Mass Cytometry in drug development and provide a foundation
to develop new applications and products, enabling our technology
to play a greater role in important clinical and translational
research that leads to better health care decision making.”
Among key growth strategies for Fluidigm is driving adoption of
the technology in clinical and translational research, as well as
accelerating consumables and assay development through increased
organic investment and partnership. Globally, mass cytometry is
utilized by 9 of the top 10 pharma companies. Mass cytometry
technologies, including CyTOF® , Imaging Mass
Cytometry and Maxpar® Direct™, have been used
in more than 160 clinical trials, including 10 utilizing IMC.
“Imaging Mass Cytometry is uniquely positioned to address the
needs of the clinical and translational research markets, and our
collaboration with ImaBiotech provides a new means to provide the
benefits of this technology to the pharma segment,” Linthwaite
said.
About FluidigmFluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information,
visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Direct, Hyperion,
Imaging Mass Cytometry, IMC, and Maxpar, are trademarks and/or
registered trademarks of Fluidigm Corporation in the
United States and/or other countries. All other trademarks are
the sole property of their respective owners. For Research Use
Only. Not for use in diagnostic procedures.
About ImaBiotechImaBiotech is a part of a
global bioanalytical CRO including Pyxant Labs with facilities in
Boston (MA), Colorado Springs (CO), Salt Lake City (UT) and Lille
(France) that offers unique bioanalytical and spatial bioanalytical
services to the pharmaceutical industry. ImaBiotech combines
innovative Mass Spectrometry Imaging, spatial biology (histology,
multi-omics, spatialomics) techniques and proprietary software
(multimaging) in order to decipher the complexity of drug
activities in heterogenous tissues. The combination of unique
capabilities with advanced digital pathology tools makes possible
the measurement of drug activity and drug response, simultaneously,
at the single cell level. This performance enables comprehensive
drug efficacy evaluation from preclinical to clinical stages. For
more information, visit imabiotech.com.
Forward-Looking Statements for
Fluidigm This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, among others, statements regarding
the benefits of a collaboration and Fluidigm technologies and
demand for Fluidigm products and services. Forward-looking
statements are subject to numerous risks and uncertainties that
could cause actual results to differ materially from currently
anticipated results, including but not limited to risks relating to
the potential adverse effects of the coronavirus pandemic on our
business and operating results, potential product performance and
quality issues; intellectual property risks; competition;
uncertainties in contractual relationships; and reductions in
research and development spending or changes in budget priorities
by customers. Information on these and additional risks and
uncertainties and other information affecting Fluidigm business and
operating results is contained in Fluidigm’s Annual Report on Form
10-K for the year ended December 31, 2020, and in its other filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Fluidigm disclaims any
obligation to update these forward-looking statements except as may
be required by law.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Fluidigm
Media:Mark SpearmanSenior Director, Corporate
Communications650 243 6621mark.spearman@fluidigm.com
Investors:Peter DeNardo415 389
6400ir@fluidigm.comImaBiotechCorinne Ramos
Innovation and Marketing Director +33 (0) 374 095
546contacts@imabiotech.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2023 to Apr 2024